Publications by authors named "Luz Hermida"

Claim this Profile
S
Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.
Robert W Frenck, Abdi Naficy, Jodi Feser, Michelle P Dickey, Victor H Leyva-Grado, Luz Hermida

Lancet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for a soluble glycoprotein vaccine to prevent disease caused by Nipah or Hendra viruses.
John H Eldridge, Michael A Egan, Demetrius Matassov, Stefan Hamm, Luz Hermida

Vaccine· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.
David K Clarke, Rong Xu, Demetrius Matassov, Theresa E Latham, Ayuko Ota-Setlik, Luz Hermida

Lancet Infect Dis· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis